entertainment -WSS

entertainment

author：comprehensive 2025-09-02 22:06:38 - browse：76

To scientists' surprise in a new study, a common genetic deletion in schizophrenia cases was linked to problems in mitochondria. Adobe

The heritable nature of schizophrenia has been known for about a century. But researchers are still trying to learn how genes that have been linked to an increased risk of the disease actually lead to schizophrenia.

For decades, those genetic underpinnings of schizophrenia have fascinated Jennifer Mulle, an associate professor at the Rutgers Center for Advanced Biotechnology and Medicine. When she was a master’s student in public health, she set out to locate a place in the DNA that held the secrets of the condition. “We did really beautifully, carefully designed studies,” she said. “And there was nothing.”

In the early 2000s, before they knew many genes factor into schizophrenia, researchers were looking for a single gene that would be culpable for the devastating illness. Mulle spent nearly a decade on the hunt, through her Ph.D. program and into her postdoctoral fellowship at Emory University. Under the mentorship of Stephen Warren, who founded the medical school’s department of human genetics and unearthed the genetics of fragile X syndrome, she finally found something.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Meta's Zuckerberg and Chan on track to put $50 billion into science

WSS

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Maker of FluMist seeks to allow at

Diversifying clinical trials isn't enough to close racial gaps: study

Vertex Pharmaceuticals may move headquarters in Boston

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Medtronic CEO on promising devices for diabetes, hypertension

Wikipedia

entertainment

Wikipedia

Psychedelics group wrestles with new pharma identity

Testing for cancer recurrence creates a new limbo for patients

Medical records are filled with copy

Patient advocates debate FDA's accelerated approval process

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Drug repurposing or repositioning? The language matters

Readout Newsletter: Merck, Vertex, and Viking updates

How one medical school became remarkably diverse

Supreme Court mifepristone arguments center on docs' right to sue

focus

Merck drug for rare lung condition set for approval in U.S.

Eliminate the waiting period for sterilization covered by Medicaid

There's no autism epidemic. It's an autism diagnosis epidemic

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Readout Newsletter: XBI biotech index, Akero Therapeutics

Maker of FluMist seeks to allow at

focus

entertainment

explore

focus